Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2020)
40 slides from Starpharma's shareholder meeting presentation, Nov 20, 2020
Slide 1: AGM Chairman's address and CEO's presentation
For personal use only AGM Chairman’s address and CEO’s presentation Melbourne, Australia; 20 November 2020: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbour
Slide 2: Chairman's Address
Chairman’s Address Starpharma Holdings Limited Annual General Meeting For personal use only 20 November 2020 On behalf of your Board of Directors, I welcome you to Starpharma’s 2020 Annual General Meeting, which is our first virtual AGM. The COVID-19 pandemic has had such a disruptive impact on our
Slide 3: Chairman's Address (continued)
such as Africa and the Middle East. While the pandemic has caused some disruption to launches, and lockdowns have had some impact on consumer demand, our global expansion for VivaGel® BV continues, and it has been very pleasing to receive so many positive product reviews by new customers and healthc
Slide 4: Chairman's Address (continued)
When I reflect on Starpharma’s recent progress, for such a small company, it is truly remarkable what has been achieved. We licensed VivaGel® BV in more than 160 countries around the world and then launched this important women’s health product in the UK, Europe, Asia, Australia and New Zealand. We
Slide 5: Annual General Meeting November 2020
For personal use only Annual General Meeting 20 NOVEMBER 2020 ASX:SPL OTC:SPHRY DR JACKIE FAIRLEY CEO 1
Slide 6: Important notice and disclaimer
Important notice and disclaimer For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”,
Slide 7: Starpharma's dendrimer platform delivers significant optionality
Starpharma’s dendrimer platform delivers significant optionality with multiple potential revenue streams, valuable products & clinical-stage assets For personal use only Key Investment Data Through innovative research and development, Starpharma is creating therapies which have the potential to impr
Slide 8: Starpharma's portfolio
Starpharma’s portfolio High-value assets including VivaGel® products on market, SPL7013 antivirals and multiple DEP® clinical assets For personal use only Extensive & growing pipeline Multiple approved of proprietary assets Multiple clinical stage assets products APPROVED PRODUCTS INTERNAL & PARTNER
Slide 9: Starpharma's strategy
Starpharma’s strategy Utilise proprietary dendrimer technology to build a portfolio of high-value products and partnerships that address important unmet patient need and create significant For personal use only commercial value EXPAND DEP® ASSETS (INTERNAL FOR LICENSING) • Strategic investment in hi
Slide 10: Starpharma responded rapidly and proactively to minimise COVID-19 impact
Starpharma responded rapidly and proactively to minimise COVID-19 impact Starpharma implemented a broad program of measures to protect the health and safety of our staff and clinical trial patients, and to ensure product supply to customers. For personal use only • Melbourne-based laboratory and in-
Slide 11: VIRALEZE preventative COVID nasal spray is virucidal
VIRALEZE™- preventative COVID nasal spray is virucidal, inactivating >99.9% of SARS-CoV-2 (coronavirus) Broad spectrum antiviral activity against multiple important respiratory viruses For personal use only including influenza and RSV MECHANISM OF ACTION VIRALEZE™ ADVANTAGES coronavirus • SPL7013 is
Slide 12: Expediting development of the VIRALEZE preventative COVID nasal spray
Starpharma is expediting the development of the VIRALEZE™ preventative COVID nasal spray EXPECTED TO BE READY FOR MARKET For personal use only 1H CY2021 Broad range of potential customers • Front-line healthcare workers; staff in high-risk environments e.g. airlines, aged care, mining, abattoirs • B
Slide 13: VIRALEZE market research shows a high level of consumer interest
VIRALEZE™- preventative nasal spray for coronavirus & other respiratory viruses VIRALEZE™ market research shows a high level of consumer interest For personal use only “Of course I would (be interested in a spray available for prevention), yeah!” “So I think wearing gloves and a mask reduces Consume
Slide 14: VIRALEZE EU consumer research: high likeability and purchase intent
VIRALEZE™ EU consumer research: High likeability and high purchase intent What is the likelihood of you buying VIRALEZE™? For personal use only • ~60% of respondents liked VIRALEZE™ Overall Gender Age % of respondents 100 • Likeability translated to high 80 47 purchase intent 57 58 55 66 63 60 Likel
Slide 15: Preventative measures critical even after an effective vaccine
COVID-19: Experts agree that preventative measures will be critical even after an effective vaccine is widely adopted For personal use only A successful vaccine against COVID-19 would be a great lifesaving advance. But vaccines alone won’t be enough to bring the crisis under control. Significant ris
Slide 16: DEP platform strategy: multiple partnerships + new products
Starpharma’s DEP® platform strategy: multiple partnerships + new products DEP® platform can be licensed to multiple partners, and be applied to multiple products in parallel, which creates exceptional optionality For personal use only INTERNAL: Starpharma uses its DEP® platform to PARTNERED: Starpha
Slide 17: DEP remdesivir
DEP® remdesivir Slow release (long-acting) & soluble version of Gilead’s remdesivir For personal use only INTERNAL Gilead’s DEPantiviral drug,versions ® enhanced remdesivir, is an of existing DEP® remdesivir is a water-soluble antiviral drug recently approved by the therapeutics nanoparticle incorpo
Slide 18: DEP partnering creates significant value and optionality
DEP® partnering creates significant value and optionality Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs, creating multiple potential revenue streams and significant IP leverage For personal use only DEP® can be used by partners to improve novel dru
Slide 19: AZD0466 outperforms in multiple cancer models
AZD0466 – AstraZeneca’s highly optimized DEP® nanoparticle formulation of a novel dual Bcl2/xL inhibitor - outperforms in multiple cancer models For personal use only AZD0466 AZD0466 OUTPERFORMS - MONOTHERAPY AZD0466 OUTPERFORMS – IN COMBINATION • a highly optimized S u D H L -4 (D L B C L X e n o g
Slide 20: AstraZeneca's AZD0466
AstraZeneca’s AZD0466 AZD0466 significantly outperformed marketed Bcl2 inhibitor venetoclax (AACR Meeting 2020) For personal use only AZD0466 has been described as having the potential to be a ‘best-in-class’ agent in this field with a broad opportunity in solid and haematological tumours (blood can
Slide 21: DEP internal: multiple clinical-stage assets
DEP® internal Multiple clinical-stage assets with high commercial value potential COMMERCIAL Utilise accelerated development / regulatory For personal use only Create value through clinical proof-of- License following proof-of-concept OBJECTIVE concept in one or more cancer types clinical data; plat
Slide 22: DEP docetaxel
DEP® docetaxel Phase 2 ongoing recruitment and positive interim results Monotherapy For personal use only Combinations Open-label trial, with the objective of establishing anti-tumour Combination DEP® docetaxel + gemcitabine trial commenced activity (efficacy) & safety 37 patients treated Based on c
Slide 23: DEP docetaxel case studies
DEP® docetaxel case studies 72-year-old woman: extensive intrahepatic 66-year-old man: stage IV oesophageal For personal use only cholangiocarcinoma, an often-fatal cancer cancer with liver metastases that affects the bile ducts Cholangiocarcinoma is a rare but aggressive form of Oesophageal cancer
Slide 24: DEP cabazitaxel
DEP® cabazitaxel Phase 2 ongoing recruitment with positive interim results For personal use only PHASE 2 Open-label trial, with the objective of establishing anti- tumour activity (efficacy) & safety Prostate cancer patient First stage will enrol 30 patients with a variety of cancers, including expe
Slide 25: DEP cabazitaxel case studies
DEP® cabazitaxel case studies 65-year-old man with late-stage 60-year-old woman with advanced For personal use only (metastatic) gastro-oesophageal cancer (metastatic) ovarian cancer Ovarian cancer has the lowest survival rate of women’s Oesophageal cancer is the seventh most commonly cancer* and is
Slide 26: DEP irinotecan
DEP® irinotecan Positive phase 1 results & phase 2 now underway POSITIVE PHASE 1 RESULTS (DOSE-ESCALATION) PHASE 2 UNDERWAY For personal use only • 7 patients were enrolled and received DEP® irinotecan at a range of doses up to 12.5 mg/m2 and up to 10 cycles of treatment each • Dose expansion: open-
Slide 27: DEP irinotecan case studies
DEP® irinotecan case studies 45-year old woman with stage IV breast For personal use only 60-year old male with stage IV oesophageal cancer with extensive liver metastases adenocarcinoma (metastatic) Oesophageal cancer is the seventh most commonly Breast cancer is the most common cancer affecting wo
Slide 28: DEP irinotecan in combination with immuno-oncology agent
DEP® irinotecan In combination with immuno-oncology agent (anti PD-1 antibody) boosts efficacy and For personal use only survival in multiple colon cancer models Figure 1: Mean Tumour Volume Over Time MC-38 These results indicate that DEP® irinotecan in combination with an anti PD-1 antibody could b
Slide 29: DEP is a technology platform with multiple commercial opportunities
DEP® is a technology platform with multiple commercial opportunities in oncology and beyond For personal use only • Antiviral e.g. DEP® remdesivir NON-ONCOLOGY • Anti-infective • Endocrinology • Franchise extension • Generic differentiation CHEMOTHERAPEUTICS • New Chemical Entities • Combinations in
Slide 30: DEP Antibody Drug Conjugates (ADC)
DEP® Antibody Drug Conjugates (ADC) DEP® ADCs further build the value of the DEP® platform For personal use only Starpharma’s DEP® technology provides enhanced therapeutic benefits to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventiona
Slide 31: DEP radiotherapeutics
DEP® radiotherapeutics DEP® is a valuable tool for radiotherapeutics and radio-diagnostics For personal use only • Starpharma has developed multiple novel DEP® radio-dendrimers radiotherapeutic and radiodiagnostic • Provide opportunities in targeted and passive approaches candidates • Applications i
Slide 32: VivaGel BV - a breakthrough product for the management of BV
VivaGel® BV - a breakthrough product for the management of BV - the most common vaginal infection worldwide For personal use only BV is caused by an imbalance of naturally occurring normal bacterial flora BV can lead to a range of medical problems including pelvic Normal BV inflammatory disease, inf
Slide 33: VivaGel BV licensed in >160 countries
VivaGel® BV licensed in >160 CY20: Further countries launches CY20: Further For personal use only around the achieved in launches world Europe – CEE & achieved in Nordic regions Asia Global market NORTH EUROPE for BV MIDDLE EAST AMERICA treatment est. to be US$750M and prevention est. to be ASIA US$
Slide 34: Positive patient experiences about VivaGel BV benefits
VivaGel® BV Positive patient experiences about VivaGel® BV benefits For personal use only “Amazing, amazing, “The pharmacist and the girls amazing…within two days I absolutely love the new symptom noticed the BV clearing up.” checker!! They all think that it will make UK customer review life much ea
Slide 35: Marketing campaigns for VivaGel BV in multiple regions
For personal use only Marketing campaigns for VivaGel® BV in multiple regions Award winning campaign FLEURSTAT BVGEL (VivaGel® BV) for the treatment of BV and relief of symptoms: Ask your pharmacist – they must decide if this product is right for you. Always read the label. Follow the directions for
Slide 36: VivaGel BV regulatory progress
VivaGel® BV regulatory progress Approved in 40 countries with multiple other submissions underway For personal use only Submitted / Approved submissions Licensed region underway UK Europe Asian countries Australia & New Zealand African & Middle Eastern countries Latin American countrie
Slide 37: VivaGel condom
VivaGel® condom VivaGel® antiviral condom launched in Japan; next launch is Europe For personal use only World’s first antiviral condom Approved for sale in Japan, Europe, Australia & Canada Partners include Okamoto, LifeStyles, Sky & Land (China) • VivaGel® antiviral condom (HIV, Herpes, HPV)
Slide 38: Financial summary
Financial summary Strong balance sheet with >$70M cash on hand* For personal use only FY20 FY19 Key Financial Data A$M A$M Revenue and other income 7.1 162% 2.7 Loss for the period (14.7) (14.3) Net operating cash outflows (10.8) (10.3) Net cash burn1 (11.2) (10.1) FY20 Result: Post FY20: • Total re
Slide 39: Outlook
Outlook VIRALEZE™ For personal use only • Expedited development and launch of VIRALEZE™ nasal spray LEVERAGE EXISTING APPROVALS VIVAGEL® COMMERCIAL OUTCOMES • Commercial roll-out of VivaGel® BV in Europe, Asia & other markets • Further regulatory approvals and launches for VivaGel® BV; building reve
Slide 40: For investor relations enquiries contact
For personal use only FOR INVESTOR RELATIONS ENQUIRIES CONTACT: Dr Jackie Fairley, CEO Nigel Baade, CFO & Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 WWW.STARPHARMA.COM ASX:SPL OTC:SPHRY 36
Starpharma Holdings — Shareholder Meeting (November 2020) on 6ix